Medicinski Centar Hipokrat-N EOOD
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Medicinski Centar Hipokrat-N EOOD in Plovdiv, clinical research in cardiovascular diseases focuses on reducing major heart and stroke risks in people with established vascular disease and irregular heart rhythm. These studies are exploring new ways to improve prevention, lower complications, and better protect patients at high risk.
- Prevention of stroke and systemic embolism in atrial fibrillation
- Lowering the risk of major cardiovascular events in atherosclerotic cardiovascular disease
- Evaluating therapies aimed at improving outcomes in established cardiovascular disease
Overall, this area is centered on testing new treatment options and measuring whether they can offer stronger protection than existing approaches.
Metabolism and Kidney Disease
The site is also active in metabolism-related research, especially studies linking kidney health with blood pressure control and protein loss in the urine. These trials are designed to slow the progression of chronic kidney disease and improve long-term kidney function for people living with advanced renal conditions.
- Slowing progression in chronic kidney disease with high blood pressure
- Reducing albuminuria and high proteinuria in kidney disease
- Testing treatments that may better preserve kidney function over time
Research in this field is aimed at improving disease control and finding more effective ways to delay kidney decline.
Bacterial Infections and Mycoses
Another important area of research at this hospital/clinic involves bacterial infections and mycoses, with a focus on preventing recurrence of Clostridioides difficile infection. The studies are intended to improve infection control and reduce the chance that this difficult-to-treat condition returns after treatment.
- Preventing recurrent Clostridioides difficile infection
- Assessing new approaches to reduce infection relapse
- Supporting better outcomes for patients with recurring intestinal infection
This line of research is centered on testing whether newer therapies can provide more reliable protection against repeat infection.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 therapeutic areas and 15 of 28 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1Novartis Pharma AG2active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG4trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Medicinski Centar Hipokrat-N EOOD
lock Showing 1 of 11 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety of Balcinrenone and Dapagliflozin Versus Dapagliflozin in Adults with Chronic Kidney Disease and Albuminuria: A Randomized, Double-Blind Study | AstraZeneca AB | Phase II | Not Recruiting | Jul 2024 | May 2025 |
IMP list
lock Showing 1 of 28 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dapagliflozin | 4 | Unknown | 2024-04-04 | 2024-07-30 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.